“…The general diagnosis of AMI in clinical practice requires the comprehensive consideration of an electrocardiogram and abnormal biomarker levels. Evidence from the scientific literature has revealed that cardiac biomarkers, e.g., myoglobin, B-type natriuretic peptide, heart-type fatty acid binding protein (h-FABP), and cardiac troponin I (cTnI), can provide a rapid diagnosis of AMI. − However, detection of the extremely small variations in the concentrations of these biomarkers during the onset of AMI remains challenging, which limits accurate diagnosis. Several techniques have been proposed for the analysis of AMI biomarkers including fluorescence, , chemiluminescence, photothermal biosensing, , and electrochemical detection. − Among these, advanced photoelectrochemical (PEC) bioanalysis enables the fusion of photodriven electrochemical responses with various biological recognition events to monitor physiological and pathological parameters, making it a promising and burgeoning technique in life science research. − Currently, developing unique signal-on sensing mechanisms is a significant research branch in PEC bioanalysis due to their reduced background signals and high sensitivity.…”